Histone Deacetylase Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the histone deacetylase inhibitor [epc] class. 4 active patents protecting 2 drugs. First major cliff: 2026. Daily refresh.

2
Drugs in class
4
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators

Acrotech Biopharma 2 patents Merck & Co. 2 patents

Cliff calendar — next 15 years

1
26
2
27
1
28

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Beleodaq
belinostat
 Acrotech Biopharma 2 73 — 2026-08-10
Zolinza
VORINOSTAT
 Merck & Co. 2 52 — 2027-03-11

Most attackable patents

Patent Drug Type Vuln Expiry
6888027 Beleodaq method of use 85 2026-08-10
8450372 Zolinza method of use 80 2028-03-18
8835501 Beleodaq formulation 60 2027-10-27
7456219 Zolinza composition of matter 27 2027-03-11

Strongest defences

Patent Drug Type Vuln Expiry
7456219 Zolinza composition of matter 27 2027-03-11
8835501 Beleodaq formulation 60 2027-10-27
8450372 Zolinza method of use 80 2028-03-18
6888027 Beleodaq method of use 85 2026-08-10

Related